内科学講座

氏名

所属

職名取得学位

膠原病・アレルギー内科分野

専門分野

主な論文・著作・業績①Hiramatsu K, Serada S, Enomoto T, Takahashi Y, Nakagawa S, Nojima S, Morimoto A, Matsuzaki S, Yokoyama T,Takahashi T, Fujimoto M, Takemori H, Ueda Y, Yoshino K, Morii E, Kimura T, Naka T. LSR antibody therapy
inhibits ovarian epithelial tumor growth by inhibiting lipid uptake. Cancer Res. 2018 Jan 15;78(2):516-527.
②Sugase T, Takahashi T, Serada S, Fujimoto M, Hiramatsu K, Ohkawara T, Tanaka K, Miyazaki Y, Makino T,Kurokawa Y, Yamasaki M, Nakajima K, Kishimoto T, Mori M, Doki Y, Naka T.
SOCS1 gene therapy improves radiosensitivity and enhances irradiation-induced DNA damage in esophageal
squamous cell carcinoma. Cancer Res. 2017 Dec 15;77(24):6975-6986.

仲哲治

内科学講座
膠原病・アレルギー内科分野

教授

博士(医学)

臨床免疫学③Fujimoto M, Serada S, Suzuki K, Nishikawa A, Ogata A, Nanki T, Hattori K, Kohsaka H, Miyasaka N, Takeuchi T,

腫瘍学Naka T. Leucine-rich α2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6biologic therapy in rheumatoid arthritis. Arthritis Rheumatol. 2015 May;67(8):2056-60④Serada S, Fujimoto M, Ogata A, Terabe F, Hirano T, Iijima H, Shinzaki S, Nishikawa T, Ohkawara T, Iwahori K,Ohguro N, Kishimoto T, Naka T. iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as anovel inflammatory biomarker in autoimmune diseases. Ann Rheum Dis. 2010 Apr;69(4):770-4.
⑤Naka T, Narasaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K,Akira S, Kishimoto T. Structure and function of a new STAT-induced STAT inhibitor. Nature. 1997 Jun26;387(6636):924-9.
① Fujimoto M, Matsumoto T, Serada S, Tsujimura Y, Hashimoto S, Yasutomi Y, Naka T. Leucine-rich alpha 2
glycoprotein is a new marker for active disease of tuberculosis. Sci Rep. 2020;10(1):3384.
② Kajimoto E, Endo M, Fujimoto M, Matsuzaki S, Fujii M, Yagi K, Kakigano A, Mimura K, Tomimatsu T, Serada S,Takeuchi M, Yoshino K, Ueda Y, Kimura T, Naka T. Evaluation of leucine-rich alpha-2 glycoprotein as a biomarkerof fetal infection. PLoS One. 2020;15(11):e0242076.
③ Lee H, Fujimoto M, Ohkawara T, Honda H, Serada S, Terada Y, Naka T. Leucine rich alpha-2 glycoprotein is a藤本

穣

内科学講座
膠原病・アレルギー内科分野

准教授

博士(医学)

臨床免疫学

potential urinary biomarker for renal tubular injury. Biochem Biophys Res Commun. 2018;498(4):1045-51.
④ Urushima H, Fujimoto M, Mishima T, Ohkawara T, Honda H, Lee H, Kawahata H, Serada S, Naka T. Leucine-richalpha 2 glycoprotein promotes Th17 differentiation and collagen-induced arthritis in mice through enhancement ofTGF-beta-Smad2 signaling in naive helper T cells. Arthritis Res Ther. 2017;19(1):137.
⑤ Fujimoto M, Serada S, Suzuki K, Nishikawa A, Ogata A, Nanki T, Hattori K, Kohsaka H, Miyasaka N, Takeuchi T,Naka T. Leucine-rich alpha2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6
biologic therapy in rheumatoid arthritis. Arthritis Rheumatol. 2015;67(8):2056-60.

内科学講座氏名

所属

職名取得学位

膠原病・アレルギー内科分野

専門分野

主な論文・著作・業績①Murata O, Suzuki K, Takeuchi T, Kudo A. Incidence and baseline characteristics of relapse or exacerbation inpatients with pulmonary sarcoidosis in Japan. Sarcoidosis Vasc Diffuse Lung Dis. 2021; 38(3)e2021026②Murata O, Suzuki K, Sugiura H, Kondo Y, Takeshita M, Yasuoka H, Yamaoka K, Koga K, Morita R, Yoshimura A,Takeuchi T. Thymus variants on imaging in patients with rheumatoid arthritis—Clinical and immunologicalsignificance. Rheumatology (Oxford). 2021 Feb 16③Murata O, Sasaki N, Sasaki K, Kowada K, Ninomiya Y, Oikawa Y, Kobayashi H, Nakamura Y, Yamauchi K.

村田興則

内科学講座
膠原病・アレルギー内科分野

講師

博士(医学)

リウマチ・Detection of cerebral microvascular lesions using 7 T MRI in patients with neuropsychiatric systemic lupus

膠原病内科学

erythematosus. Neuroreport. 2015 Jan 7;26(1):27-32④Murata O, Izumi K, Kaneko Y, Yasuoka H, Suzuki K, Matsubara S, Yamaoka K, Takeuchi T. Microscopic
polyangiitis diagnosed by muscle specimen: a case report and literature review. Modern Rheumatology CaseReports. 2:2, 181-184⑤Sugai M, Murata O, Oikawa H, Katagiri H, Matsumoto A, Nagashima H, Sugai T, Maemondo M. A case of bonemarrow involvement in sarcoidosis with crescentic glomerular lesions. Respir Med Case Rep. 2020 Aug
28;31:101202①Suzuki Y, Kakisaka K, Sato T, Mikami R, Abe H, Sasaki T, Takikawa Y. Tc-99m GSA scintigraphy within the first 3
days after admission as an early predictor of outcome in severe acute liver injury. Sci Rep. 2021;11:12518.
②Suzuki Y, Kakisaka K, Suzuki A, Takahara T, Sasaki T, Sato T, Yonezawa T, Nitta H, Takikawa Y. A Lille model for
predicting the response of severe alcoholic hepatitis to corticosteroid treatment in Japanese patients. Hepatol Res.

肝臓病学
鈴木悠地

内科学講座
膠原病・アレルギー内科分野

特任講師

博士(医学)

再生医療
分子生物学

2019;49:758-764③Sasaki T, Suzuki Y, Kakisaka K, Wang T, Ishida K, Suzuki A, Abe H, Sugai T, Takikawa Y. IL-8 inducestransdifferentiation of mature hepatocytes toward the cholangiocyte phenotype. FEBS Open Bio. 2019;9:21052116.
④Suzuki Y, Katagiri H, Wang T, Kakisaka K, Kume K, Nishizuka SS, Takikawa Y. Ductular reactions in the liver
regeneration process with local inflammation after physical partial hepatectomy. Lab Invest. 2016;96:1211-1222.
⑤2020年度科学研究助成事業(科研費)．若手，研究代表者：鈴木悠地，研究期間：②020-2022年度，胚盤胞補完法を用いた移植可能な肝臓制作技術の開発

内科学講座氏名

所属

職名取得学位

膠原病・アレルギー内科分野

専門分野

主な論文・著作・業績①Ito I, Nakaoka Y, Doi Y, et al. Primary Cardiac Lymphoma: A Lesson Learned from an Unsuccessful Experience.
Internal Medicine. 2018; 57(24): 3569-3574.
②伊藤いづみ, 中岡洋子, 土居義典, ほか. 心臓原発悪性リンパ腫. 別冊日本臨牀 循環器症候群（第3版）（Ⅲ）. 日本臨
牀社. (2019)

伊藤いづみ

内科学講座
膠原病・アレルギー内科分野

助教

学士(医学）

内科学一般関連③Ito I, Doi Y, et al. Primary Cardiac Lymphoma: Early Initiation of Chemotherapy is Critical to Save Lives of

循環器内科学関連

Patients. American College of Cardiology (ACC). March, 2017. Washington, DC, America.
④伊藤いづみ, 今井龍一郎, 土居義典, ほか. 上肢深部静脈血栓症の治療にCatheter-directed Thrombolysisが有効であった若年女性例, 第65回日本心臓病学会学術集会, 2017年9月, 大阪.
➄伊藤いづみ, 古島知樹, 北岡裕章, ほか. OCTとIVUSの画像所見が得られた特発性冠動脈解離の一例, 第24回日本心血管インターベンション治療学会 中国・四国地方会, 2017年9月, 岡山.
1. Lee H, Fujimoto M, Ohkawara T, Honda H, Serada S, Terada Y, Naka T. Leucine rich α-2 glycoprotein is apotential urinary biomarker for renal tubular injury. Biochem Biophys Res Commun 2018 Apr 15;498(4):1045-1051.
2 .Sugase T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hiramatsu K, Nishida T, Hirota S, Saito Y, Tanaka K,Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Hanasaki K, Kishimoto T, Mori M, Doki Y, NakaT.SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through
FAK/PI3 K signaling.Gastric Cancer 2018 Nov;21(6):968-976.
3. Nakagawa S, Serada S, Kakubari R, Hiramatsu K, Sugase T, Matsuzaki S, Matsuzaki S, Ueda Y, Yoshino K,Ohkawara T, Fujimoto M, Kishimoto T, Kimura T, Naka T.

大河原知治

内科学講座
膠原病・アレルギー内科分野

助教

学士（医学）

膠原病内科学

Intratumoral delivery of an adenoviral vector carrying the SOCS-1 gene enhances Tcell-mediated anti-tumor
immunity by suppressing. Molecular Cancer Therapeutics 2018 Sep;17(9):1941-1950.
4. Sugase T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hiramatsu K, Koh M, Saito Y, Tanaka K, Miyazaki Y,Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Hanazaki K, Mori M, Doki Y, Naka T.Lipolysis-stimulated
lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutictarget in gastric cancer.Oncotarget 2018 Aug 31;9(68):32917-32928.
［和文］
1.大河原知治, 仲哲治 サイトカインの生理活性

免疫系2359) 2004; 別冊サイトカイン-state of arts : 71-74.

SOCSによる免疫制御

現況と展望 医学のあゆみ(0039-